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Summary. — Boron Neutron Capture Therapy is an experimental form of radio-
therapy based on the enrichment of tumor cells with 10B and on the subsequent
irradiation with thermal neutrons. The neutron capture reaction in 10B gives rise to
two high-LET particles which can deliver a lethal dose to the tumor, substantially
sparing the normal tissues. The selectivity of the therapy is due to the capacity of
certain drugs to vehiculate the boron inside the tumor more than in the normal cells.
This characteristic makes BNCT an option for tumors that have presently no cure,
because surgery, conventional radiotherapy or chemotherapy are not applicable or
are not much effective. One of these cases is represented by diffuse tumors, such
as metastatic spreads invading entire organs. At the University of Pavia, a long
research has been carried out to apply BNCT to different kinds of diffuse tumors,
such as liver metastases. Two patients affected by this pathology were treated at
the TRIGA reactor of the University. This paper describes the state-of-art of BNCT
research in Pavia and the recent project for BNCT of osteosarcoma.
PACS 87.53.Jw – Therapeutic applications, including brachytherapy.
PACS 87.53.Bn – Dosimetry/exposure assessment.
PACS 87.55.dh – Tissue response.
PACS 87.56.jk – Field shaping.
1. – Introduction
Boron Neutron Capture Therapy (BNCT) [1] is an experimental radiotherapy based
on a two-step procedure: infusion of the patient with a 10B carrier and irradiation of the
tumor target with thermal neutrons. The carrier must be able to concentrate boron in
tumor cells more than in normal ones. The thermal neutron capture in 10B takes place
with a cross section of 3834 b, and the two high LET particles rising from the reaction
10B, (n, α)7Li, have a range in tissue comparable to a typical cell diameter. This way,
the tumor cells absorb a lethal radiation dose, and the high-LET particles which are
produced inside them, do not cause damage to the surrounding cells. BNCT selectivity
is not due to the radiation field, as in conventional radiotherapy, but rather to boron bio-
distribution obtained with the used carrier. If the drug is effective in concentrating boron
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in tumor more than in normal tissue, the irradiation will target the tumor wherever it is
located in the target, even if it is disseminated within the normal tissue. This situation
is typical in case of metastatic spreads or when the tumor is infiltrative. In these cases,
surgery is difficult and often not resolutive.
BNCT is currently applied to different kinds of tumors, such as head and neck recur-
rent cancer, brain tumors, skin melanoma. The countries in which clinical trials are being
carried on are: Finland [2], Japan [3] and Argentina [4]. There are many research projects
all over the world to apply BNCT to lung [5], oral [6], liver [7] and bone [8] tumors.
BNCT research started in Pavia(1) during the eighties, with the aim to set-up a treat-
ment able to treat all the metastases from colon carcinoma invading the liver. In fact,
the primary tumor affecting the colon gives rise to hepatic metastases in a large percent-
age of cases, and almost always the patient has a poor prognosis because the organ is
completely invaded and not operable. As the metastases are multifocal and often they
are too small to be detected, the possibility to irradiate the entire organ, after the tumor
enrichment with 10B, could be a good solution. To this purpose, an innovative technique
based on the organ explantation, followed by irradiation and re-implantation in the pa-
tients was conceived. Although this method presents many advantages, it is clear that
the patients have to undergo a very invasive surgery. Another class of tumors that could
take advantage from BNCT are lung tumors. Many primary tumors and metastastic
spreads invading lungs are not curable with the available techniques, moreover standard
radiotherapy is limited by the positions of the lungs, close to very radiosensitive organs.
In this case, BNCT can be conceived as an external radiotherapy, because the lung tissue
has a low density compared to other soft tissues, and it is possible to obtain a uniform
thermal neutron field inside the lung irradiating with multiple epithermal external neu-
tron beams. The research in this field started in Pavia some years ago and the feasibility
study is being performed. The preliminary results indicate that the therapy is feasible
and the conditions for the clinical applications are being set. Another kind of tumor that
could be a target for BNCT is osteosarcoma of the limb. The patients that are affected
by this tumor have an average age of 19 years, and even if the percentage of cure is
about 80%, there are still many patients who have to undergo total limb amputation.
Furthermore, due to the infiltrative nature of the tumor, some cells surviving surgery and
chemotherapy may give rise to recurrences and pulmonary metastases, which decrease
the probability of survival. In this case, being the tumor well localized around the knee,
the neutron beam can be relatively small and built at the TRIGA reactor in Pavia.
The BNCT activities at Pavia University are supported by INFN (National Institute
for Nuclear Physics), with different experiments for liver (TAOrMINA and ELBA) and
lung (WIDEST) and by MIUR (Italian Ministry for University and Research), with 2
PRIN and 2 FIRB projects funded since 2005. Moreover, a research project to test
a boron carrier with a Gd group to perform in vivo boron quantification by magnetic
resonance, is active and it is funded by CARIPLO.
(1) The research work described in this paper is carried out by a group of Physicists made up
of: S. Altieri, F. Ballarini, P. Bruschi, M. A. Gadan, N. Protti, D. Santoro, S. Stella, M. Bonora,
F. Borsa, M. Corti. Being a very multi-tasking kind of work, the research is performed together
with Biologists: C. Ferrari, L. Cansolino, A. M. Clerici, C. Zonta and Medical Doctors: J. G.
Bakeine, A. Zonta.
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2. – Boron concentration measurement
The boron concentration measurement is a critical issue in BNCT: the accurate knowl-
edge of boron content in normal and tumor tissue allows to prepare a proper treatment
plan, delivering a lethal dose to the tumor and a dose below the tolerance level to the
healthy organs. In Pavia, two techniques are currently used: α spectroscopy [9] and
neutron autoradiography [10]. The first is a quantitative measurement and exploits the
neutron capture reaction occurring in samples of tissues properly prepared and irradi-
ated in the reactor. The frozen samples of organ are cut with a Leica cryostat in 60μm
sections, deposited on mylar disks. The samples are placed inside a rotating device,
facing a thin silicon detector. The whole system is under vacuum. The chamber is then
irradiated in a position of the thermal column where the thermal neutron flux is about
2 · 109 cm−2 s−1. A remote control allows to rotate the device, and each sample is irra-
diated facing the detector tipically for 10 minutes. After this interval of time, the device
is rotated and the next sample faces the detector. During the irradiation, the detector
collects the charged particles coming from the reactions 10B(n, α)7Li and 14N(n,p)14C
and their residual energy spectra are recorded on-line. The obtained spectra have the
characteristic shape of absorbed spectra, because the sample thickness is larger than the
range of the charged particle in tissue. The boron concentration in the sample irradiated
is evaluated analysing the spectrum, in particluar the parts of it where only α-particles
contribute, and taking into account the thermal neutron flux, the cross section of the
capture, and the efficency of the equipment.
The other technique is a qualitative method to visualize boron bio-distribution in
tissue samples. It consists of depositing tissue sections 60μm thick on CR-39 films which
are only sensitive to high LET radiation (SSNTD [11]). The samples on the CR-39 are
irradiated in the thermal column of the TRIGA reactor, in the same position as the
samples for α spectrometry. The α-particles, the lithium ions and the protons coming
from the neutron capture in boron and nitrogen, produce latent tracks in the CR-39.
An etching in Na-OH solution makes the tracks visible, creating an image of the boron
distribution in the sample: areas of the tissues with higher boron concentration, produce
a higher tracks density which results in darker areas in the image. The parameters to be
adjusted in order to optimize the images are the neutron fluence, the etching time and
temperature, the concentration of the NaOH solution. In order to evaluate the selective
uptake in tumor, a neutronigraphic image is compared to a histological preparation of a
tissue section cut just after the irradiated one. It is thus possible to correlate the tumor
nodules recognizable in the histology to the darker areas present in the CR-39 (fig. 1).
The two described methods are combined in the case of mixed tumor samples, where
viable tumor cells, healthy cells and necrosis may be simultaneously present. In this
case it would be impossible to separate boron concentration in active tumor cells from
boron concentration in normal tissue only by a spectroscopy measurement. Preparing
three sections, one for spectrometry, one for auto neutronigraphy and one for histology,
it is possible to measure the area occupied by tumor in the sample used for spectroscopy,
and to properly weight the contribution of healthy tissue and tumor in the average con-
centration measured. This is accomplished measuring boron concentration in a healthy,
uniform tissue sample and using this value to calculate the boron concentration in tumor.
In the last 2 years, another branch of BNCT research was opened in Pavia. It is in
fact well known, that a substantial improvement of BNCT will be reached when boron
concentration will be measured in vivo by an imaging method such as MRI or PET.
To this end, an experiment was started in collaboration with biologists, chemists and
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Fig. 1. – Comparison between the histological preparation of a lung section with tumor nodules
(right) and the neutronigraphy of a subsequent section (left). The three circular darker struc-
tures on the left correspond to the three tumor nodules on the right, demonstrating that tumor
cells uptake higher boron concentration with respect to normal tissue.
physicists to create a new BPA molecule bound to a Gd atom. In this way the Gd
concentration could be measured by NMR and correlated to boron concentration [12].
The molecule was synthesized and it was proved in vitro to be uptaken and to be visible
to NMR spectroscopy. The next steps will be a quantitative measurement by NMR
on cell cultures and then in rat tissues, using the boron measurement methods already
assessed as inter-calibration system.
3. – Liver BNCT
The possibility to uniformly irradiate an organ and selectively hit the tumor cells,
represents the only option to cure patients affected by hepatic metastases from colon
adenoscarcinoma. In Pavia, an innovative BCNT method was assessed, which foresees the
infusion of the patient with a boron carrier (Borophenylalanine, BPA), the explantation
of the organ, the irradiation of the liver inside the thermal column of the TRIGA reactor,
and the re-implantation of the organ in the patient [13]. A long pre-clinical research was
performed in order to assess the boron pharmacokinetics in liver: rats both healthy and
bearing tumor were injected with BPA (300mg/kg) and were sacrificed after different
intervals of time. The boron concentration was then measured in samples taken from
the rat livers, frozen in liquid nitrogen and cut for the measurement. Using the methods
described above, the ratio of boron concentration in tumor and the boron concentration
in liver as a function of the time elapsed after BPA infusion was obtained: between 2
and 4 hours, this ratio is maximum, and higher than 4. This is the optimal interval of
time to wait after BPA administration, before irradiating the organ. The facility for the
organ irradiation was obtained inside the thermal column of the reactor, building a 1
meter long channel with a cross section of 40 × 20 cm2 (fig. 2). Two Bismuth screens
were placed at the end of the channel to stop the γ radiation coming from the core.
Using this facility, two patients affected by multiple liver metastases were treated
in 2001 and 2003 [14, 15]. In both cases the metastases were completely destroyed: a
CT scan performed few days after the treatment evidenced that the tumor nodules had
been replaced by necrotic tissue. The first patient survived with a good quality of life
for 44 months after BNCT, despite the very poor prognosis before BNCT, due to the
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Fig. 2. – (Colour on-line) Section of the irradiation facility obtained in the Thermal Column of
the TRIGA reactor, University of Pavia. It is visible the liver placed in the irradiation position
inside the channel and the two bismuth screens, protecting it from the γ radiation coming from
the core (pink walls between the reactor core and the liver). The reactor was fully simulated by
MCNP.
dissemination of the metastases in the whole liver. Then he died for a general recurrency
of the tumor in different organs. The second patient, although BNCT succedeed in de-
stroying the metastases, died in 33rd post operative day for a cardiac failure. Obviously
two treatments do not allow to draw conclusions as in a complete clinical trial, never-
theless the CT scan of the livers without tumor nodules just after the organ irradiation
is a clear demonstration of the BNCT effectiveness in treating tumors that, nowadays,
have no other treatment options.
Waiting for other patients to be treated, BNCT research for liver metastases is be-
ing carried out measuring boron concentration in human liver samples, in collaboration
with the Mainz University, where the liver irradiation is being pursued at their TRIGA
reactor [16]. A protocol is active at the University Hospital of Mainz, which allows to
administrate BPA to patients who have to undergo partial resection of the liver. After
surgery, the portion of the liver which is removed is analyzed by neutron autoradiogra-
phy, ICP-OES [17], PGNAA [18], and α spectrometry to measure boron uptake in human
tumor and liver. This activity represents an important step in the field of BNCT because
for the first time, an intercomparison of boron measurement methods is being performed
on human tissues. The preliminary results show a substantial agreement between the
different methods used.
4. – Lung BNCT
The other branch of the BNCT research in Pavia is dedicated to lung tumors, which
are one of the major causes of death for cancer in the Western Countries [19]. In many
cases, the lung is invaded by metastases or disseminated tumors which cannot be removed,
and also chemotherapy is often not effective. The lung tissue has a density about three
times lower than other soft tissues, as liver, and this makes it possible to conceive a BNCT
treatment without explantation. Irradiating with epithermal external neutron beams it
is possible to obtain a uniform thermal neutron field inside the organ. To demonstrate
this, a set of Monte Carlo simulations was performed, using an antropomorphic model
named ADAM, kindly provided by ENEA, Bologna [20], and the neutron transport code
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Fig. 3. – MCNP transversal view of ADAM’s thorax, with the two ideal collimated epithermal
beams for lung BNCT irradiation. The dashed line indicates the longitudinal axis of the lung,
along which the uniformity of the thermal neutron field was studied.
MCNP.4c2 [21]. ADAM’s thorax was divided into 1 cm3 voxels and the simulated source
consisted of 2 collimated, epithermal (1 keV) opposite neutron beams (antero-posterior
and postero-anterior) as shown in fig. 3. This ideal set-up was used to demonstrate the
possibility to irradiate uniformly the whole lung, allowing to fully exploit the potentiality
of BNCT: the tumor receives a lethal dose wherever it may be, while the normal tissue
is not seriously damaged. Assuming a boron concentration ratio between tumor and
healthy tissue of 3 [22], the ratio of the biological weighted dose absorbed by tumor and
the one absorbed by lung is still about 3. This means that, in principle, it is possible to
perform BNCT using external beams to treat tumors disseminated in the lung.
The feasibility of BNCT depends obiously on the boron concentration ratio obtained
between tumor and lung. To study this issue, a number of rats, both healthy and bearing
lung metastases, were injected with BPA and sacrificed after different interval of times.
Their lungs were taken, frozen in liquid nitrogen, and prepared for boron measurements
by α spectroscopy and neutron autoradiography. As anticipated before, from 4 hours
after BPA administration, the boron concentration ratio remains higher than 3 up to 8
hours. This result, together with the possibility to obtain a uniform thermal neutron
field inside the lung, encourages to go on with the research.
The next step is the in vivo effectiveness study, to test the capacity of BNCT to
destroy the metastases and to evaluate its effects both on tumor and on normal tissue.
Some rats will be irradiated in the thermal column of the TRIGA reactor, in a proper
shielding with a window for lung irradiation. The rats will be divided into 3 groups:
a control group with lung metastases which will not receive any treatment, a group
with metastases which will be irradiated without boron and a third group which will
receive the entire BNCT treatment. The shielding was studied by means of Monte Carlo
calculations [23]. Presently, the shielding box is available and all the permissions to
irradiate the animals at the reactor have been obtained.
5. – Osteosarcoma BNCT
Osteosarcoma is a highly malignant tumor constituted by malignant mesenchymal
cells which produce osteoid and bone tissue. It is the most common primary malignant
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tumor of the skeleton with an average age of the patients of about 19 years. The global
mean survival at 5 years is 55–70%. However, when pulmonary metastases occur, the
survival is reduced to less than 30% in 80% of the cases. Usually, osteosarcoma is treated
by surgery combined to chemotherapy. In 80% of cases the operation is limb salvage
(without amputation), but when the tumor affects also vessels and nerves, the limb
amputation is still necessary. BNCT could be a valid option in this field, because, after
finding a good carrier of boron able to enrich osteosarcoma cells, its effectiveness lies
on high-LET radiation. Moreover, it would be possible to irradiate with a proper beam
a larger part of the limb, to decrease the probability that some cells could survive to
the surgery. A project for BNCT of osteosarcoma was recently funded by the Italian
Ministry of University and Research in the program FIRB-Futuro in Ricerca. It is aimed
to: verify the osteosarcoma BNCT feasibility, establish the conditions for the clinical
applications of BNCT for the limb osteosarcoma, and complete the pre-clinical research
and the design of the patient irradiation facility at the TRIGA reactor in Pavia. Not
only this research is ment to contribute to the cure of limb osteosarcoma, but also to
increase the effectiveness of BNCT developing new boron carriers. In fact, the project
was conceived in collaboration between Pavia and Florence University, where a group of
chemists will formulate and characterize new boronated compounds that will be tested
both in vitro and in vivo in Pavia. The first measurements of boron concentration in cells
cultured in presence of BPA have already been performed, proving that also osteosarcoma
cells uptake boron if vehiculated by BPA [24].
6. – Conclusions
Boron Neutron Capture Therapy is a highly multi-tasking research involving physi-
cists, biologists, chemists and medical doctors. The state of the art is that BNCT is still
an experimental radiotherapic technique, and some work has still to be done before it
can be considered a conventional therapy. Considerable improvements in this direction
will be reached when carriers able to concentrate boron in the tumor much more than
BPA will be formulated. Moreover, it will be necessary to measure boron concentration
in-vivo by an imaging method just before the neutron irradiation. These issues are being
addressed in Pavia, in the framework of BNCT research for liver and lung metastases
and for limb osteosarcoma.
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